XGN (Exagen) Cyclically Adjusted Revenue per Share: $4.67 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGN Exagen Inc XGN
62 GF Score
Price $4.68
GF Value $3.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exagen Cyclically Adjusted Revenue per Share?

Exagen XGN -5.45% 62 Cyclically Adjusted Revenue per Share is $4.67 as of Mar. 2026. GuruFocus rates XGN with a GF Score™ of 62/100 and a GF Value™ of $3.00 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Exagen's adjusted revenue per share for the three months ended in Mar. 2026 was $0.725. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.67 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-25), Exagen's current stock price is $4.68. Exagen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $4.67. Exagen's Cyclically Adjusted PS Ratio of today is 1.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Exagen was 2.66. The lowest was 0.58. And the median was 1.20.


Exagen  (NAS:XGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exagen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.68/4.67
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Exagen was 2.66. The lowest was 0.58. And the median was 1.20.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Exagen Cyclically Adjusted Revenue per Share Related Terms


Exagen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Exagen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exagen Cyclically Adjusted Revenue per Share Chart

Exagen Annual Data
Trend Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.53

Exagen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.50 4.50 4.53 4.67

XGN vs BNR, IMDX, IDXG: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Exagen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exagen Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exagen's Cyclically Adjusted PS Ratio falls into.


XGN
62GF Score
Exagen Inc XGN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exagen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exagen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.725/330.2130*330.2130
=0.725

Current CPI (Mar. 2026) = 330.2130.

Exagen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.239 236.293 0.334
201406 0.404 238.343 0.560
201409 0.630 238.031 0.874
201412 0.727 234.812 1.022
201503 0.749 236.119 1.047
201506 0.766 238.638 1.060
201509 0.799 237.945 1.109
201512 0.763 236.525 1.065
201712 0.000 246.524 0.000
201809 1.410 252.439 1.844
201812 1.653 251.233 2.173
201903 1.588 254.202 2.063
201906 0.932 256.143 1.202
201909 6.900 256.759 8.874
201912 0.813 256.974 1.045
202003 0.761 258.115 0.974
202006 0.708 257.797 0.907
202009 0.852 260.280 1.081
202012 1.001 260.474 1.269
202103 0.818 264.877 1.020
202106 0.754 271.696 0.916
202109 0.723 274.310 0.870
202112 0.747 278.802 0.885
202203 0.612 287.504 0.703
202206 0.446 296.311 0.497
202209 0.862 296.808 0.959
202212 0.747 296.797 0.831
202303 0.641 301.836 0.701
202306 0.801 305.109 0.867
202309 0.758 307.789 0.813
202312 0.772 306.746 0.831
202403 0.803 312.332 0.849
202406 0.829 314.175 0.871
202409 0.685 315.301 0.717
202412 0.741 315.605 0.775
202503 0.835 319.799 0.862
202506 0.816 322.561 0.835
202509 0.752 324.800 0.765
202512 0.705 324.054 0.718
202603 0.725 330.213 0.725

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.67 mean?
Exagen (XGN) has a Cyclically Adjusted Revenue per Share of $4.67 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Exagen and its competitors.
Is Exagen's Cyclically Adjusted Revenue per Share too high?
Exagen's current Cyclically Adjusted Revenue per Share is $4.67. Overall, Exagen has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exagen's Cyclically Adjusted Revenue per Share compare to BNR and IMDX?
Exagen's Cyclically Adjusted Revenue per Share of $4.67 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Exagen and its competitors. Exagen's current Cyclically Adjusted Revenue per Share is $4.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exagen stock overvalued right now?
Based on GuruFocus' analysis, Exagen (XGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $4.68 — trading 56% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.67. Exagen's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Exagen (XGN), the current Cyclically Adjusted Revenue per Share is $4.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $4.68 is trading 56% above its estimated GF Value™ of $3.00. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Cyclically Adjusted Revenue per Share: $4.67
  • GF Value™: $3.00 vs. price of $4.68 (56% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
62GF Score

Get the complete analysis for XGN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.68
Price
$3.00
GF Value